Skip to main content

Table 1 Cytotoxicity in OSCC cells treated with or without metformin and cisplatin or mitomycin C

From: Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones)

Compounds

LD50(μM)

WHCO1

WHCO5

SNO

Cisplatin

70.88 ± 13.8

p = 0.009

11.68 ± 3.62

p = 0.075

11.01 ± 1.62

p = 0.0001

Met + Cisplatin

126.02 ± 26.57

28.03 ± 15.81

28.16 ± 3.37

Mitomycin C

32.73 ± 2.49

p = 0.003

32.87 ± 3.03

p = 0.25

9.92 ± 1.80

p = 0.011

Met + Mitomycin C

37.15 ± 0.79

30.19 ± 4.36

16.64 ± 2.77

  1. OSCC cells were treated with 10 mM metformin (Met) and either cisplatin or mitomycin C and MTT assays performed. LD50 (μM) was calculated on replicates (n = 3, mean ± SD).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us